Table 3 To calculate the number of points for each category of main effects.
Risk factor | Categories | Reference value (Wij) | \({\beta }_{i}\) | \({\beta }_{i}({W}_{ij}-{W}_{iREF})\) | Pointsij = \({\beta }_{i}({W}_{ij}-{W}_{iREF})/B\) |
|---|---|---|---|---|---|
Socio-demographic factors | |||||
Age | 0.03 | ||||
40–44 | 42 = W1REF | 0 | 0 | ||
45–49 | 47 | 0.15 | 1 | ||
50–54 | 52 | 0.30 | 2 | ||
55–59 | 57 | 0.45 | 3 | ||
60–64 | 62 | 0.60 | 4 | ||
65–69 | 67 | 0.75 | 5 | ||
70–74 | 72 | 0.90 | 6 | ||
75–79 | 77 | 1.05 | 7 | ||
80–84 | 82 | 1.20 | 8 | ||
85–89 | 87 | 1.35 | 9 | ||
90–94 | 92 | 1.50 | 10 | ||
Duration of type 2 diabetes | |||||
0 | 0 = W2REF | 0 | 0 | ||
1–5 | 1 | 0.06 | 0.06 | 0 | |
> 5 | 2 | 0.24 | 0.24 | 2 | |
Renal function markers | |||||
eGFR (mL/min/1.73 m2) | |||||
≥ 90 | 0 = W3REF | 0 | 0 | ||
< 90 | 1 | 0.84 | 0.84 | 6 | |
ACR (mg/g) | |||||
< 30 | 0 = W4REF | 0 | |||
≥ 30 | 1 | 1.05 | 1.05 | 7 | |
Lipid profiles | |||||
HDL-C (mg/dl) | |||||
≥ 40 (male) ≥ 50 (female) | 0 = W5REF | 0 | 0 | ||
< 40 (male) < 50 (female) | 1 | 0.18 | 0.18 | 1 | |
Triglyceride (mg/dl) | |||||
< 150 | 0 = W6REF | 0 | 0 | ||
≥ 150 | 1 | 0.31 | 0.31 | 2 | |
Variation in glycemic factors | |||||
Variation of HbA1c (%) | |||||
≤ 3.9 | 0 = W7REF | 0 | 0 | ||
4.0–8.0 | 1 | 0.19 | 0.19 | 1 | |
> 8.0 | 2 | 0.31 | 0.31 | 2 | |
Variation of fasting plasma glucose (%) | |||||
≤ 10.7 | 0 = W8REF | 0 | 0 | ||
10.8–20.3 | 1 | 0.10 | 0.10 | 1 | |
> 20.3 | 2 | 0.34 | 0.34 | 2 | |
Baseline diabetes-related disorders or complications | |||||
Diabetes retinopathy | |||||
No | 0 = W9REF | 0 | 0 | ||
Yes | 1 | 0.29 | 0.29 | 2 | |
Medication use | |||||
Insulin use | |||||
No | 0 = W10REF | 0 | 0 | ||
Yes | 1 | 0.39 | 0.39 | 2 | |
Anti-hypertension drug use | |||||
No | 0 = W11REF | 0 | 0 | ||
Yes | 1 | 0.20 | 0.20 | 1 | |
